Sentences with phrase «in the tumor whose»

Not exact matches

Merck took a precision approach and targeted its medication towards patients whose tumors express the PD - L1 protein, enrolling these individuals in clinical trials.

But a late - stage clinical trial called CheckMate - 026 for the drug failed to meet its primary goal of halting cancer progression in advanced, untreated patients whose tumors consisted of at least 5 % PD - L1.

Unlike Ruth Levy, whose lung cancer caused her no physical pain, Mr. Smith's tumor pressed against his spine and kept him in agony much of the time.

Two other reports in the same issue of Cancer Causes and Control suggest that children born to mothers who eat at least one hot dog per week during pregnancy have double the normal risk of developing brain tumors, as do children whose fathers ate hot dogs before conception.

Republicans with exploratory committees include Danbury Mayor Mark Boughton, whose $ 33,790 in the third quarter brought his total to $ 195,941 (Boughton underwent surgery to remove a brain tumor during the quarter); State Sen. Toni Boucher of Wilton ($ 43,336 third quarter, $ 58,890 total) and Norwalk's Steve Obsitnik, who raised $ 63,696 in the third quarter and $ 265,363 to date.

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

Next, the team tested the GD2 CAR - T cells in mice whose brainstem was implanted with human DIPG tumors, an experimental system that Monje's lab pioneered.

While nivolumab improved survival rates in the overall study population, it appeared to be most successful in patients whose tumors were positive for the human papillomavirus (HPV).

An early - stage clinical study by another institution, published in the Lancet Oncology in May 2016, combined chemotherapy with an experimental drug that blocks CCR2, a receptor on monocytes and macrophages whose activation stimulates these cells to infiltrate tumors.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

Heeke says the study would be open to people whose tumors have evidence of HRD like those found in this study, which includes bladder, breast, cervix, liver and bile duct, colorectal, endometrial, gastric / esophageal, head & neck, kidney, neuroendocrine, lung, ovarian, pancreas, prostate, sarcoma, and thyroid cancers, as well as gastrointestinal stromal tumors, glioma, melanoma and unknown primary cancers.

Another important aspect of the green - light KTP laser approach, Zeitels adds, is that biopsy and treatment of patients whose cancer involves a single vocal cord usually can be accomplished in the same procedure, whereas radiotherapy requires a prior biopsy to determine the extent and location of the tumor, followed by daily radiation treatments over approximately six weeks.

«By helping us understand that lower levels of RNF125 confer resistance to BRAF inhibitors, we have a new strategy to stratify patients for currently approved therapy versus participation for human clinical trials to investigate whether targeting JAK1 will be more effective in patients whose tumors exhibit reduced RNF125,» said Keith T. Flaherty, M.D., associate professor, Harvard Medical School, and director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, and co-author of the study.

It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less?

By performing a genome - wide screen in breast cancer cells, Dr. Oesterreich and her colleagues identified a gene called HOXC10 as one that the cancer seems to modify to allow continued tumor growth in patients whose cancer becomes resistant to traditional therapies.

The Mütter Museum of medical anomalies at the venerable College of Physicians of Philadelphia is well supplied with helpful staff and airy colonnades, but what it could really use is a little stack of printed leaflets explaining to the modern visitor how he or she is supposed to feel about all this, or at least what to make of it: the uprooted genitalia and beach - ball tumors, the skeleton of the man whose muscle has turned to bone, the woman so fat that after death her body transformed itself into soap, the embryos in jars whose peeling labels break the sad but unsurprising news that not having a skull, or a brain, or a stomach, or any skin, is a state of affairs «incompatible with life.»

In a 2011 vaccine trial of patients whose primary pancreatic tumors were surgically removed, «we found antibodies against annexin A2 in those who had received the vaccine and who also had demonstrated long - term, disease - free survival after receiving the vaccines,» explains ZhenIn a 2011 vaccine trial of patients whose primary pancreatic tumors were surgically removed, «we found antibodies against annexin A2 in those who had received the vaccine and who also had demonstrated long - term, disease - free survival after receiving the vaccines,» explains Zhenin those who had received the vaccine and who also had demonstrated long - term, disease - free survival after receiving the vaccines,» explains Zheng.

Patients in clinical remission — whose tumors have disappeared or are significantly reduced in size — are given a course of immune treatment after a six - month rest period following chemotherapy.

At Colchester General Hospital, the researchers looked at MR scans taken both before treatment and six weeks after the patients had completed chemotherapy and radiotherapy, and found that the patients whose tumors were less heterogeneous — ie more uniform — in terms of texture parameters six weeks after treatment were more likely to survive longer.

He was part of a team that recognized that only about 10 % of patients with NSCLC responded to the small molecule erlotinib — those whose tumors harbored mutations in the gene encoding EGFR.

Genomic data from the HeLa cell line are also being released with the final version of the paper as a result of discussions between leaders of the National Institutes of Health (NIH) and relatives of Henrietta Lacks, from whose cervical tumor the original HeLa cell line was derived prior to her death in 1951.

The research team developed a new method called highly multiplexed single - nucleus sequencing (HM - SNS) to investigate CNA's clonal substructure and evolution in a cohort of 12 TNBC patients, whose tumors had been surgically removed prior to further therapy.

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

If we validate this study in similar, but larger groups of patients, we can develop a test based for CFS breaks; the results would allow us to place patients in one of two categories: those whose tumors do not have CFS breaks and who would likely do well with local treatment alone (e.g. radiotherapy or surgery); and, those patients whose tumors do have CFS breaks and would need a more complex treatment protocol, in addition to RT or surgery, to combat distant spread.»

In the largest study of its kind, researchers led by the University of Pennsylvania School of Nursing have investigated the caregivers of 186 mothers to childhood brain tumor survivors aged 14 - 40 whose care needs last long into adulthood.

One exception — a man with colon cancer whose metastatic tumors vanished for several years after he was treated in 2007 — piqued researchers» interest.

«We have found that 10 % of colon and stomach tumors present the loss of a molecule called TP53TG1, whose function in healthy cells is to prevent activation of YBX1 protein.

To explore this idea, Hopkins oncologists Dung Le, Luis Diaz, and others looked for mismatch repair mutations in tumor samples from patients with advanced colon cancer and other cancer types whose tumors had stopped responding to other treatments.

Applying their technique to head and neck cancers, they've discovered seven new tumor - suppressor genes whose role in cancer was previously unknown.

Modeling APC, a gene whose role in lung cancer is not as well understood, revealed that APC loss also drives tumor progression.

The new test, which examines cancer - related DNA and proteins in the blood, yielded a positive result about 70 % of the time across eight common cancer types in more than 1000 patients whose tumors had not yet spread.

About 1,000 patients whose tumor characteristics most closely match one of the 20 or so gene - targeting drugs offered in the study will be put into groups of about 30 patients to get that drug.

If further research in the mice bears out, they could soon be tested in children whose brain tumors also show a decrease in ATRX production.

In addition, some CFSs overlap tumor suppressor genes, whose inactivation further fuels tumor progression.

Of the 22 patients whose tumors successfully grafted, six died before data from the mice were available, but in 13 of the remaining 16 cases, there was a positive correlation between mouse and human results.2 In a second study, performed in collaboration with Manuel Hidalgo of the Spanish National Cancer Research Center, the team found that 6 of 13 patients with advanced solid tumors who were treated based on results from personalized PDX mice had partial tumor remissions, even in cases where genetic sequencing of the tumor showed no actionable mutationsin 13 of the remaining 16 cases, there was a positive correlation between mouse and human results.2 In a second study, performed in collaboration with Manuel Hidalgo of the Spanish National Cancer Research Center, the team found that 6 of 13 patients with advanced solid tumors who were treated based on results from personalized PDX mice had partial tumor remissions, even in cases where genetic sequencing of the tumor showed no actionable mutationsIn a second study, performed in collaboration with Manuel Hidalgo of the Spanish National Cancer Research Center, the team found that 6 of 13 patients with advanced solid tumors who were treated based on results from personalized PDX mice had partial tumor remissions, even in cases where genetic sequencing of the tumor showed no actionable mutationsin collaboration with Manuel Hidalgo of the Spanish National Cancer Research Center, the team found that 6 of 13 patients with advanced solid tumors who were treated based on results from personalized PDX mice had partial tumor remissions, even in cases where genetic sequencing of the tumor showed no actionable mutationsin cases where genetic sequencing of the tumor showed no actionable mutations.3

The Joslin team found that intestinal tumors grow just as quickly in a mouse cancer model whose «epithelial» cells lining the inside of the intestine have been genetically modified so that insulin can't activate the cells.

An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK - 228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and / or a TSC2 Mutation

A lot of effort in tumor stem cell research has always been directed to finding a so - called marker, a molecule whose presence on a cell reliably identifies it as a cancer stem cell.

We've found through trials that a complete response is difficult to achieve, but patients whose tumors shrink by 30 percent can experience a major increase in quality of life.

Vescor, advised by its scientific founders White and Kimmelman, whose research has shown inhibition of autophagy can dramatically impact tumor growth in pre-clinical models, will develop small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug (IND) enabling studies, and move these into clinical development.

One of these 8 cases was from patient UPN 933124, which we informally call «AML1» and whose primary tumor was the first cancer genome to be published, also by our group, back in 2008.

The recommendation is due in large part to a growing body of evidence demonstrating the clinical benefit of treating patients whose tumors harbor this alteration with targeted therapy.

These findings for scoring expression were agreed with Gillet et al., 1996 [24], who stated in their study that, moderate / strong staining of Cyclin D1 had a longer relapse - free survival than patients whose tumors stained weakly or negatively for Cyclin D1 with a great significant difference (P = 0.007).

The investigators also identified alteration in NTRK genes that drove tumor development in young HGG patients whose tumors developed outside the brainstem.

Mar. 12, 2015 — Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt - Ingram Cancer Center (VICC) investigators.

Radiation Therapy Prolongs Life in Men with Recurrent Prostate Cancer Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence.

In combination with this approach, inhibitors of DNA methylation and / or histone deacetylases are expected to relieve repression of DAPK tumor suppressors, whose epigenetic silencing has emerged as a recurring theme from our work and throughout the literature.

Since completing the initial paper published Thursday, the team has analyzed 50 more samples from eye fluid of retinoblastoma patients, including those with less aggressive tumors whose eyes were saved, to get a start on determining what factors might be at play in tumor progression.

Vogelstein has gone on to investigate additional genes involved in colon cancer such as APC, mutations of which lead to colorectal tumors, and PIK3CA, whose mutations turn benign tumors malignant.

Examining expression levels of H2AX in breast cancer tumor data from The Cancer Genome Atlas, a large National Institutes of Health database containing genetic information about tumor tissue from more than 11,000 patients, the Roswell Park team found that breast cancer patients whose tumors had high levels of H2AX had a significantly worse prognosis than those with low levels.